In "Science Business," Gary P. Pisano delves into the heart of the biotechnology industry's underwhelming performance, despite its groundbreaking promise and potential. Through a lens that is both critical and enlightening, Pisano explores the unique challenges that have hindered the sector, from the financing of high-risk, long-term R&D investments to the fast-paced evolution of drug science knowledge. This book not only offers an in-depth analysis of the industry's intricate workings but also shines a light on the systemic issues that have stifilled its growth and innovation. Pisano goes beyond mere critique, providing a blueprint for revitalization that hinges on the adoption of new business models and organizational structures tailored to the biotech landscape's distinct nature. He argues for a paradigm shift towards integration and sustained learning over the short-term gains of intellectual property monetization. "Science Business" is a call to action for biotech firms, investors, universities, pharmaceutical giants, and government regulators alike, championing a collaborative approach to overhaul the industry. The reward, Pisano suggests, is a brighter future where the biotech industry fulfills its promise, leading to significant advancements in healthcare and human well-being.